Immunotherapy combinations for the treatment of patients with solid tumors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Duan J, Cui L, Zhao X et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 6(3), 375–384 (2019).
  Google Scholar
• 2. Sun L, Zhang L, Yu J et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci. Rep. 10(1), 2083 (2020).
  Medline CASGoogle Scholar
• 3. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275–4280 (2010).
  Medline CASGoogle Scholar
• 4. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4(5), 336–347 (2004).
  Medline CASGoogle Scholar
• 5. Lee KM, Chuang E, Griffin M et al. Molecular basis of T cell inactivation by CTLA-4. Science 282(5397), 2263–2266 (1998).
  Medline CASGoogle Scholar
• 6. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
  Medline CASGoogle Scholar
• 7. Gotwals P, Cameron S, Cipolletta D et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer. 17(5), 286–301 (2017).
  Medline CASGoogle Scholar
• 8. Attili I, Passaro A, Pavan A, Conte P, De Marinis F, Bonanno L. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): does biological rationale meet clinical needs? Crit. Rev. Oncol. Hematol. 119, 30–39 (2017).
  MedlineGoogle Scholar
• 9. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14(8), 561–584 (2015).
  Medline CASGoogle Scholar
• 10. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 541(7637), 321–330 (2017).
  Medline CASGoogle Scholar
• 11. Liu P, Zhao L, Pol J et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat. Commun. 10(1), 1486 (2019).
  MedlineGoogle Scholar
• 12. Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15(5), 310–324 (2018).
  Medline CASGoogle Scholar
• 13. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8(9), 1069–1086 (2018).
  MedlineGoogle Scholar
• 14. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377(14), 1345–1356 (2017). •• CheckMate 067 was the first study to show improved survival with the combination ipilimumab and nivolumab establishing a standard first line treatment option for patients with metastatic melanoma.
  Medline CASGoogle Scholar
• 15. Long GV, Atkinson V, Cebon JS et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet. Oncol. 18(9), 1202–1210 (2017).
  Medline CASGoogle Scholar
• 16. Tannir NM, Frontera OA, Hammers HJ et al. Thirty-month follow-up of the Phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 37(Suppl. 7), 547 (2019).
  MedlineGoogle Scholar
• 17. Overman MJ, Lonardi S, Wong KYM et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 36(8), 773–779 (2018).
  Medline CASGoogle Scholar
• 18. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381(21), 2020–2031 (2019).
  Medline CASGoogle Scholar
• 19. Peters S, Cho BC, Reinmuth N et al. Abstract CT074: tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. Cancer Res. 79(Suppl. 13), CT074 LP-CT074 (2019).
  Google Scholar
• 20. Owonikoko TK, Kim HR, Govindan R et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, rand. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30(Suppl. 2), ii77 (2019).
  Google Scholar
• 21. Licitra LF, Haddad RI, Even C et al. EAGLE: a Phase III, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). J. Clin. Oncol. 37(Suppl. 15), 6012 (2019).
  Google Scholar
• 22. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Groups. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 16(5), 1743–1751 (1998).
  Medline CASGoogle Scholar
• 23. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  Medline CASGoogle Scholar
• 24. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33(17), 1889–1894 (2015).
  Medline CASGoogle Scholar
• 25. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase III trial. Lancet. Oncol. 16(4), 375–384 (2015).
  Medline CASGoogle Scholar
• 26. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
  Medline CASGoogle Scholar
• 27. Schachter J, Ribas A, Long GV et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label Phase III study (KEYNOTE-006). Lancet 390(10105), 1853–1862 (2017).
  Medline CASGoogle Scholar
• 28. Robert C, Ribas A, Schachter J et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, Phase III study. Lancet. Oncol. 20(9), 1239–1251 (2019).
  Medline CASGoogle Scholar
• 29. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381(16), 1535–1546 (2019).
  Medline CASGoogle Scholar
• 30. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
  Medline CASGoogle Scholar
• 31. Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1116–1127 (2019).
  Medline CASGoogle Scholar
• 32. Motzer RJ, Penkov K, Haanen J et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1103–1115 (2019).
  Medline CASGoogle Scholar
• 33. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378(14), 1277–1290 (2018). • CheckMate 214 shows improved survival with the combination ipilimumab and nivolumab establishing an effective first-line treatment option for patients with poor risk metastatic renal cancer.
  Medline CASGoogle Scholar
• 34. Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A. The clinical impact of the genomic landscape of mismatch repair-deficient cancers. Cancer Discov. 8(12), 1518–1528 (2018).
  Medline CASGoogle Scholar
• 35. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 57(21), 4749–4756 (1997).
  Medline CASGoogle Scholar
• 36. Koopman M, Kortman GAM, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100(2), 266–273 (2009).
  Medline CASGoogle Scholar
• 37. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 497(7447), 67–73 (2013).
  MedlineGoogle Scholar
• 38. Bonneville R, Krook MA, Kautto EA et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis. Oncol. Vol1 (2017).
  Google Scholar
• 39. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415–421 (2013).
  Medline CASGoogle Scholar
• 40. Kloor M, von Knebel Doeberitz M. The immune biology of microsatellite-unstable cancer. Trends in Cancer 2(3), 121–133 (2016).
  MedlineGoogle Scholar
• 41. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91(12), 2417–2422 (2001).
  Medline CASGoogle Scholar
• 42. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 43. Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase II study. Lancet. Oncol. 18(9), 1182–1191 (2017).
  Medline CASGoogle Scholar
• 44. Collaboration GB of DC. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 5(12), 1749–1768 (2019).
  MedlineGoogle Scholar
• 45. Ramalingam SS, Yang JC-H, Lee CK et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. JCO2017747576 (2017).
  Google Scholar
• 46. Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377(9), 829–838 (2017).
  Medline CASGoogle Scholar
• 47. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
  Medline CASGoogle Scholar
• 48. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
  Medline CASGoogle Scholar
• 49. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).
  Medline CASGoogle Scholar
• 50. Reck M, Rodriguez-Abreu D, Robinson AG et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37(7), 537–546 (2019).
  Medline CASGoogle Scholar
• 51. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018). •• KEYNOTE 189 was the first study to demonstrate a survival benefit for chemoimmunotherapy combination in metastatic nonsquamous NSCLC establishing the standard first-line treatment for unselected patients.
  Medline CASGoogle Scholar
• 52. Mok TSK, Wu Y-L, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase III trial. Lancet 393(10183), 1819–1830 (2019).
  Medline CASGoogle Scholar
• 53. Hellmann MD, Rizvi NA, Goldman JW et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, Phase I, multicohort study. Lancet Oncol. 18(1), 31–41 (2017).
  Medline CASGoogle Scholar
• 54. Vokes NI, Liu D, Ricciuti B et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis. Oncol. 3, 1–12 (2019).
  Google Scholar
• 55. Horn L, Mansfield AS, Szczesna A et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379(23), 2220–2229 (2018). •• The IMpower133 is the first study showing improved survival with chemoimmunotherapy establishing a new standard of care beyond platinum-etoposide regimens that have been the sole treatment option for patients with advanced SCLC since the 1980s.
  Medline CASGoogle Scholar
• 56. Paz-Ares L, Dvorkin M, Chen Y et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase III trial. Lancet. 394(10212), 1929–1939 (2019).
  Medline CASGoogle Scholar
• 57. Ready NE, Ott PA, Hellmann MD et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J. Thorac. Oncol. 15(3), 426–435 (2019).
  MedlineGoogle Scholar
• 58. Hellmann MD, Callahan MK, Awad MM et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 33(5), 853–861.e4 (2018).
  Medline CASGoogle Scholar
• 59. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116–1127 (2008).
  Medline CASGoogle Scholar
• 60. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377(25), 2500–2501 (2017).
  MedlineGoogle Scholar
• 61. Oliva M, Spreafico A, Taberna M et al. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann. Oncol. 30(1), 57–67 (2019).
  Medline CASGoogle Scholar
• 62. Ferris RL, Licitra L, Fayette J et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. Clin. Cancer Res. An Off. J. Am. Assoc. Cancer Res. 25(17), 5221–5230 (2019).
  CASGoogle Scholar
• 63. Chung HC, Ros W, Delord JP et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol. 37(17), 1470–1478 (2019).
  Medline CASGoogle Scholar
• 64. Naumann RW, Oaknin A, Meyer T et al. Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358. Proc. Eur. Soc. Med. Oncol. 30(Suppl. 5), v851–v934 (2019).
  Google Scholar
• 65. Kim TJ, Cho KS, Koo KC. Current status and future perspectives of immunotherapy for locally advanced or metastatic urothelial carcinoma: a comprehensive review. Cancers 12(1), 192 (2020).
  CASGoogle Scholar
• 66. Sharma P, Siefker-Radtke A, de Braud F et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J. Clin. Oncol. 37(19), 1608–1616 (2019).
  Medline CASGoogle Scholar
• 67. Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J. Cell. Mol. Med. 23(8), 4854–4865 (2019).
  MedlineGoogle Scholar
• 68. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74–88 (2013).
  Medline CASGoogle Scholar
• 69. Roselli M, Cereda V, di Bari MG et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2(10), e27025 (2013).
  MedlineGoogle Scholar
• 70. Peng J, Hamanishi J, Matsumura N et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-B to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75(23), 5034–5045 (2015).
  Medline CASGoogle Scholar
• 71. Dumoulin DW, Visser S, Cornelissen R et al. Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic non-squamous cell NSCLC. J. Thorac. Oncol. (2020). https://www.sciencedirect.com/science/article/pii/S1556086420303361
  MedlineGoogle Scholar
• 72. West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, Phase III tria. Lancet Oncol. 20(7), 924–937 (2019).
  Medline CASGoogle Scholar
• 73. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).
  Medline CASGoogle Scholar
• 74. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018). •• KEYNOTE 407 was the first study to demonstrate a survival benefit for chemoimmunotherapy combination in metastatic squamous NSCLC establishing the standard first-line treatment for unselected patients.
  Medline CASGoogle Scholar
• 75. Papadimitrakopoulou V, Cobo M, Bordoni R et al. OA05.07 IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage iv non-squamous NSCLC. J. Thorac. Oncol. 13(10), S332–S333 (2018).
  Google Scholar
• 76. Cortés J, Lipatov O, Im S-A et al. LBA21 – KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann. Oncol. 30, v859–v860 (2019).
  MedlineGoogle Scholar
• 77. Schmid P, Adams S, Rugo HS et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mT). J. Clin. Oncol. 37(Suppl. 15), 1003 (2019).
  Google Scholar
• 78. Gadgeel S, Garassino MC, Esteban E et al. O.03 KEYNOTE-189: OS update and progression after the next line of therapy (PFS2) with pembrolizumab + chemotherapy for metastatic nonsquamous NSCLC. J. Thorac. Oncol. 14(11), S1153 (2019).
  Google Scholar
• 79. Gadgeel S, Rodríguez-Abreu D, Speranza G et al. Updated analysis from KEYNOTE 189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer. J. Clin. Oncol. 38(14), 1505–1517 (2020).
  Medline CASGoogle Scholar
• 80. Jotte R, Cappuzzo F, Vynnychenko I et al. OA14.02 IMpower131: final OS results of carboplatin + nab-paclitaxel ± atezolizumab in advanced squamous NSCLC. J. Thorac. Oncol. 14(10), S243–S244 (2019).
  Google Scholar
• 81. Reck M, Ciuleanu T-E, Dols MC et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J. Clin. Oncol. 38(15_suppl), 9501 (2020).
  Google Scholar
• 82. Aguilar EJ, Ricciuti B, Gainor JF et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30(10), 1653–1659 (2019).
  Medline CASGoogle Scholar
• 83. Provencio-Pulla M, Nadal-Alforja E, Cobo M et al. Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): a Phase II multicenter exploratory study-NADIM study-SLCG. J. Clin. Oncol. 36(Suppl. 15), 8521 (2018).
  Google Scholar
• 84. Peters S, Felip E, Dafni U et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer 133, 83–87 (2019).
  Medline CASGoogle Scholar
• 85. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence metastatic TNBC. Clin. Cancer Res. 13(15 Pt 1), 4429–4434 (2007).
  MedlineGoogle Scholar
• 86. Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 10, 25–36 (2016).
  Medline CASGoogle Scholar
• 87. Caulfield SE, Davis CC, Byers KF. Olaparib: a novel therapy for metastatic breast cancer in patients with a BRCA1/2 mutation. J. Adv. Pract. Oncol. 10(2), 167–174 (2019).
  MedlineGoogle Scholar
• 88. Kim I, Sanchez K, McArthur HL, Page D. Immunotherapy in triple-negative breast cancer: present and future. Curr. Breast Cancer Rep. 11(4), 259–271 (2019).
  Google Scholar
• 89. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108–2121 (2018). • The IMpassion 130 established this regimen as first-line therapy for patients with PD-L1-positive breast cancer and is the current standard of care regimen for patients with advanced TNBC.
  Medline CASGoogle Scholar
• 90. Burtness B, Harrington KJ, Greil R et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase III study. Lancet 394(10212), 1915–1928 (2019). •• This trial established pembrolizumab monotherapy and/or combination with chemotherapy as a standard first-line option for recurrent or metastatic SCCHN.
  Medline CASGoogle Scholar
• 91. Cancer Genome Atlas Network Genomic classification of cutaneous melanoma. Cell 161(7), 1681–1696 (2015).
  MedlineGoogle Scholar
• 92. Robert C, Grob JJ, Stroyakovskiy D et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381(7), 626–636 (2019).
  Medline CASGoogle Scholar
• 93. Ribas A, Daud A, Pavlick AC et al. Extended 5-year follow-up results of a Phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin. Cancer Res. 26(1), 46–53 (2020).
  Medline CASGoogle Scholar
• 94. Frederick DT, Piris A, Cogdill AP et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. An Off. J. Am. Assoc. Cancer Res. 19(5), 1225–1231 (2013).
  CASGoogle Scholar
• 95. Koya RC, Mok S, Otte N et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 72(16), 3928–3937 (2012).
  Medline CASGoogle Scholar
• 96. Song C, Piva M, Sun L et al. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov. 7(11), 1248–1265 (2017).
  Medline CASGoogle Scholar
• 97. Kuske M, Westphal D, Wehner R et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol. Res. 136, 151–159 (2018).
  Medline CASGoogle Scholar
• 98. Karachaliou N, Pilotto S, Teixidó C et al. Melanoma: oncogenic drivers and the immune system. Ann. Transl. Med. 3(18), 265 (2015).
  MedlineGoogle Scholar
• 99. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368(14), 1365–1366 (2013).
  Medline CASGoogle Scholar
• 100. Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 28(5), 611–612 (2015).
  MedlineGoogle Scholar
• 101. Ascierto PA, Ferrucci PF, Fisher R et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25(6), 941–946 (2019).
  Medline CASGoogle Scholar
• 102. Sullivan RJ, Hamid O, Gonzalez R et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25(6), 929–935 (2019).
  Medline CASGoogle Scholar
• 103. Mazieres J, Drilon A, Lusque A et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30(8), 1321–1328 (2019).
  Medline CASGoogle Scholar
• 104. Gettinger S, Hellmann MD, Chow LQM et al. Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 13(9), 1363–1372 (2018).
  Google Scholar
• 105. Oxnard GR, Yang JC-H, Yu H et al. TATTON: a multi-arm, Phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 31(4), 507–516 (2020).
  Medline CASGoogle Scholar
• 106. Spigel DR, Reynolds C, Waterhouse D et al. Phase I/II study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of ALK translocation-positive advanced non-small cell lung cancer (CheckMate 370). J. Thorac. Oncol. (2018).
  Google Scholar
• 107. Kim D-W, Gadgeel SM, Gettinger SN et al. Safety and clinical activity results from a Phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). J. Clin. Oncol. 36(Suppl. 15), 9009 (2018).
  Google Scholar
• 108. Shaw AT et al. Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. J. Clin. Oncol. 36, (Suppl. 15), 9008–9008 (2018).
  Google Scholar
• 109. Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 15(11), 694–708 (2018).
  Medline CASGoogle Scholar
• 110. Reck M, Mok TSK, Nishio M et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label Phase III trial. Lancet. Respir. Med. 7(5), 387–401 (2019).
  Medline CASGoogle Scholar
• 111. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 112. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11(10), 702–711 (2011).
  Medline CASGoogle Scholar
• 113. Wallin JJ, Bendell JC, Funke R et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
  Medline CASGoogle Scholar
• 114. Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med 382(20), 1894–1905 (2020).
  Medline CASGoogle Scholar
• 115. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115–124 (2007).
  Medline CASGoogle Scholar
• 116. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369(8), 722–731 (2013).
  Medline CASGoogle Scholar
• 117. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised Phase III trial. Lancet. Oncol. 14(6), 552–562 (2013).
  Medline CASGoogle Scholar
• 118. Morse MA, Sun W, Kim R et al. The role of angiogenesis in hepatocellular carcinoma. Clin. Cancer Res. An Off. J. Am. Assoc. Cancer Res. 25(3), 912–920 (2019).
  CASGoogle Scholar
• 119. Rini BI, Powles T, Atkins MB et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, Phase III, randomised controlled trial. Lancet 393(10189), 2404–2415 (2019).
  MedlineGoogle Scholar
• 120. McGregor BA, McKay RR, Braun DA et al. Results of a multicenter Phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. J. Clin. Oncol. 38(1), 63–70 (2019).
  MedlineGoogle Scholar
• 121. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 122. Finn RS, Ducreux M, Qin S et al. IMbrave150: a randomized Phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. J. Clin. Oncol. 36(Suppl. 15), TPS4141–TPS4141 (2018). •• This trial established a new SOC for patients with unresectable HCC.
  Google Scholar
• 123. Makker V, Rasco D, Vogelzang NJ et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, Phase II trial. Lancet. Oncol. 20(5), 711–718 (2019).
  Medline CASGoogle Scholar
• 124. Brose MS, Vogelzang NJ, DiSimone C et al. A Phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer. J. Clin. Oncol. 37(Suppl. 8), 16 (2019).
  Google Scholar
• 125. Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag. Res. 11, 7707–7719 (2019).
  Medline CASGoogle Scholar
• 126. Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, Phase II trial. Lancet Oncol. 17(11), 1558–1568 (2016).
  Medline CASGoogle Scholar
• 127. Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J. Med. Econ. 21(12), 1191–1205 (2018).
  MedlineGoogle Scholar
• 128. Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D'Haene N. Methods of measurement for tumor mutational burden in tumor tissue. Transl. Lung Cancer Res. 7(6), 661–667 (2018).
  Medline CASGoogle Scholar
• 129. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19(3), 133–150 (2019).
  Medline CASGoogle Scholar
• 130. Yarchoan M, Albacker LA, Hopkins AC et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cu pancers. JCI Insight 4(6), e126908 (2019).
  MedlineGoogle Scholar
• 131. Kather JN, Suarez-Carmona M, Charoentong P et al. Topography of cancer-associated immune cells in human solid tumors. Elife 7, e36967 (2018).
  MedlineGoogle Scholar
• 132. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, Phase II randomised controlled trial. Lancet 387(10030), 1837–1846 (2016).
  Medline CASGoogle Scholar
• 133. Vargas FA, Furness AJS, Litchfield K et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33(4), 649–663.e4 (2018).
  MedlineGoogle Scholar
• 134. Zhu J, Pabla S, Labriola M et al. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 37(Suppl. 15), 2595–2595 (2019).
  Google Scholar
• 135. Rodig SJ, Gusenleitner D, Jackson DG et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10(450), eaar3342 (2018).
  MedlineGoogle Scholar
• 136. Skoulidis F, Goldberg ME, Greenawalt DM et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8(7), 822–835 (2018).
  Medline CASGoogle Scholar
• 137. Skoulidis F, Arbour KC, Hellmann MD et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J. Clin. Oncol. 37(Suppl. 15), 102 (2019).
  Google Scholar
• 138. Mezquita L, Auclin E, Ferrara R et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 4(3), 351 (2018).
  MedlineGoogle Scholar
• 139. Mezquita L, Arbour K, Auclin E et al. 1407PDerived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. Ann. Oncol. 29(Suppl. 8), (2018).
  Google Scholar
• 140. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371), 91–97 (2018).
  Medline CASGoogle Scholar
• 141. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18(3), 197–218 (2019).
  Medline CASGoogle Scholar
• 142. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18(1), 155 (2019).
  MedlineGoogle Scholar